Mary Lou Ackerman

Saint Elizabeth Health Care

Steeve Asselin

National Research Council

Erik Atkinson

National Research Council
Industrial Technology Advisor 

Paul Barran

National Research Council

Barry Billings

Saint Elizabeth Health Care

Anthony Briggs

University of Alberta

Colin Coros

A unique not-for-profit, TEC Edmonton is a joint venture of the University of Alberta and the Edmonton Economic Development Corporation. TEC Edmonton helps technology entrepreneurs accelerate their growth. In addition to being the commercialization agent for University of Alberta technologies, TEC Edmonton operates Greater Edmonton's largest accelerator for early stage technology companies, including both university spinoffs and companies from the broader community. TEC Edmonton provides client services in four broad areas: Business development, funding and finance, technology commercialization and entrepreneur development. In 2015, TEC Edmonton was identified by the Swedish University Business Incubator (UBI) Index as the 4th best university business incubator in North America, and was also named Canadian "Incubator of the Year" at the 2014 Startup Canada Awards.

About the TEC Health Accelerator: A program of TEC Business Development, the TEC Health Accelerator connects life sciences startups and researchers with health-service providers like Alberta Health Services, health research funders like Alberta Innovates - Health Solutions, life-science investors and multi-national health care companies looking for new products.

For more information, visit www.tecedmonton.com.

TEC Edmonton
Executive in Residence 

Catherine De Varennes

National Research Council

Jason Ding

A unique not-for-profit, TEC Edmonton is a joint venture of the University of Alberta and the Edmonton Economic Development Corporation. TEC Edmonton helps technology entrepreneurs accelerate their growth. In addition to being the commercialization agent for University of Alberta technologies, TEC Edmonton operates Greater Edmonton's largest accelerator for early stage technology companies, including both university spinoffs and companies from the broader community. TEC Edmonton provides client services in four broad areas: Business development, funding and finance, technology commercialization and entrepreneur development. In 2015, TEC Edmonton was identified by the Swedish University Business Incubator (UBI) Index as the 4th best university business incubator in North America, and was also named Canadian "Incubator of the Year" at the 2014 Startup Canada Awards.

About the TEC Health Accelerator: A program of TEC Business Development, the TEC Health Accelerator connects life sciences startups and researchers with health-service providers like Alberta Health Services, health research funders like Alberta Innovates - Health Solutions, life-science investors and multi-national health care companies looking for new products.

For more information, visit www.tecedmonton.com.

TEC Edmonton
Executive in Residence; Program Director, TEC Health Accelerator 

Dr. Klaus Fiebig Canada

The Ontario Bioscience Innovation Organization (OBIO®) is focused on the development of an integrated health innovation economy for Ontario, Canada. The OBIO Capital Access Advisory Program (CAAPTM) is led by OBIO and a North American Steering Committee of life science venture capitalists and serial entrepreneurs to position selected high-potential bioscience companies for financing success. 

Dr. Klaus Fiebig
Ontario Bioscience Innovation Organization
LinkedIn logo Senior Director 
BIO

Dr. Fiebig is an entrepreneur and biopharma executive with over 14 years of management experience in academia, industry and not-for-profit (government) organizations.  He is the Senior Director, Strategic Programs at the Ontario Bioscience Innovation Organization (OBIO) and leads OBIO’s Capital Access Advisory Program which has received significant support from FedDev Ontario to strengthen Ontario’s cadre of investable human health technology companies, increasing high value deal flow.  Prior to his role at OBIO, Dr. Fiebig was CSO and VP of Research Programs at Ontario Genomics, a government funding organization, where he oversaw an $800M research program portfolio.  During this time he was responsible for more than 10 funding competitions, a team of research program managers, and Ontario Genomics’ strategic approach to identifying, cultivating, and raising funds for genomics and proteomics projects and platforms in Ontario.  As Senior Director, Structural Biology and Computational Chemistry at Affinium Pharmaceuticals in Toronto he led the structural biology and computational chemistry teams and a 20 FTE strategic alliance with Pfizer on structure-based drug discovery focused on infectious disease.  Prior, Dr. Fiebig founded and managed MRPharm GmbH, a fee-for-service and drug discovery biotech start-up in Frankfurt, Germany and was a lead scientist with Xencor in Los Angeles responsible for improving their automatic computational protein design platform.  Dr. Fiebig has a broad scientific background in the physical and biomedical fields. He trained at Yale University (Post Doctorate), Oxford University (Post Doctorate), University of California at San Francisco (PhD), and the Technical University Munich (undergraduate). He co-authored numerous scientific publications and holds several patents.